Skip to content

Study on the minimum effective concentration/volume of ropivacaine hydrochloride for Spinal Anesthesia in anal day surgery

Study on the minimum effective concentration/volume of ropivacaine hydrochloride for Spinal Anesthesia in anal day surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074796
Enrollment
Unknown
Registered
2023-08-16
Start date
2023-09-02
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal fistula?Perianal abscess?Hemorrhoids

Interventions

Case series:None

Sponsors

Chongqing Fengdu County People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-65 years. (2) Patients who are to undergo anal fistulotomy/hanging wire, rectal perianal abscess incision and drainage, external hemorrhoidectomy/internal hemorrhoidectomy, etc. (3) ASA grade I-II. (4) No serious cardiovascular or cerebrovascular disease and no contraindication to intralesional anesthesia. (5) Patients or their families have full understanding of the purpose and significance of this trial, voluntarily participate in this clinical trial, and sign the informed consent form. Translated with www.DeepL.com/Translator (free version)

Exclusion criteria

Exclusion criteria: (1) Patient or family refusal to participate in this clinical trial. (2) Pre-operative combined neurological or psychiatric disorders (e.g. schizophrenia, depression), history of psychotropic and narcotic drug abuse. (3) Patients with preoperative combined neuromuscular disorders (epilepsy, Parkinson's disease, myasthenia gravis, myasthenia gravis syndrome, etc.) and severe dementia or cognitive impairment. (4) Pre-operative combination of severe pulmonary disease, traumatic brain injury, history of cerebral infarction or history of neurosurgery. (5) Those unable to communicate because of visual, hearing, or speech impairment (6) Severe liver failure (Child-Pugh class C) (7) Severe renal failure (requiring replacement therapy) (8) Women who are pregnant or breastfeeding. (9) Participation in clinical trials of other drugs within 3 months. (10) Allergy to drugs such as local anesthetics. (11) Patients with a body mass index (BMI) = 30 kg/M2. (12) Combined peripheral neuropathy. (13) History of puncture site infection, trauma or surgery, HIV infection. Translated with www.DeepL.com/Translator (free version)

Design outcomes

Primary

MeasureTime frame
Modified Bromage Rating;MEV90;

Secondary

MeasureTime frame
VAS score of pain at the beginning of surgery;nausea and vomiting during and after operation;Persistent abnormal sensation of perineum and lower limbs;Persistent lower limb weakness;

Countries

China

Contacts

Public ContactShaojin Bu

Fengdu County People's Hospital

1296644677@qq.com+86 139 9679 4673

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026